News

Currently, DKSH is managing Roche’s entire supply chain operations for pharmaceutical products and distribution to hospitals, clinics and pharmacies in the region. According to DKSH, the agreement will

Imbruvica, which is now approved throughout the 28 European Union (EU) member states, is indicated for CLL patients who have received at least one prior therapy, or in

Embeda is used to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The updated label states that

Anoro Ellipta is a combination of long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA). The 24-week, blinded, parallel group, multicenter trial evaluated the efficacy and safety of

EZH2 is a histone methyltransferase (HMT), which will play a potentially oncogenic role in a number of cancers such as germinal centre (GC) non-Hodgkin lymphomas, INI1-deficient cancers such

The drug has also been designated an orphan drug by the US Food and Drug Administration (FDA) to treat pancreatic cancer and small-cell lung cancer. The company claims

Granted marketing authorization under the trade-name Sovaldi in December 2013, Harvoni is a combination of the NS5A inhibitor ledipasvir and the nucleotide analog polymerase inhibitor sofosbuvir. The marketing

The company’s ANDA product is a generic version of Pfizer and Tris Pharma’s Quillivant XR, which is a central nervous system (CNS) stimulant indicated to treat attention deficit

Currently, OPS202 is evaluated in Phase I/II clinical trials and is based on a new next generation antagonistic somatostatin analog with improved receptor binding to sst2. The company